Trials / Terminated
TerminatedNCT01571635
Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( β)- Thalassemia.
A Phase 2A, Open-label Dose Finding Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With BETA(b)-THALASSEMIA.
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 46 (actual)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Dose finding study to determine the safety and tolerability of Sotatercept (ACE-011) in adults with Beta (β)-Thalassemia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SOTATERCEPT (ACE-011) | 0.1 mg/kg to 1.5mg/kg Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period. |
Timeline
- Start date
- 2012-10-10
- Primary completion
- 2015-07-02
- Completion
- 2022-05-24
- First posted
- 2012-04-05
- Last updated
- 2023-06-18
- Results posted
- 2023-06-18
Locations
18 sites across 4 countries: France, Greece, Italy, United Kingdom
Source: ClinicalTrials.gov record NCT01571635. Inclusion in this directory is not an endorsement.